Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Capecitabine + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + oxaliplatin is a combination chemotherapy regimen commonly referred to as CAPOX or XELOX. It consists of two drugs: - Capecitabine (an oral prodrug of 5-fluorouracil) and - Oxaliplatin (a platinum-based chemotherapeutic agent). This combination is primarily used for the treatment of colorectal cancer but is also indicated for other gastrointestinal cancers such as gastric and biliary tract cancers. Capecitabine works by being converted in the body to 5-fluorouracil, which inhibits DNA synthesis in rapidly dividing cells. Oxaliplatin causes DNA crosslinking and damage through its platinum moiety, leading to apoptosis in cancer cells. Together, these agents target rapidly dividing tumor cells via complementary mechanisms that disrupt DNA replication and repair[1][2][3][5][6].
- Brand names
- XELOXCAPOX
- Other names
- CapeOxcapecitabine + oxaliplatin
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Capecitabine + oxaliplatin.